Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hutchison MediPharma Receives $6 Million Milestone from Janssen

publication date: Oct 10, 2013
Hutchison MediPharma, a division of Chi-Med, will receive a $6 million milestone payment from Janssen Pharma. The payment was triggered by a small-molecule candidate with an inflammation/immunology target that Janssen in-licensed from HMP in 2010. Although HMP has not disclosed the target, the company did say it could receive up to $90.5 million in additional clinical and approval milestones from the partnership. If the drug is approved, HMP will be paid royalties on sales. More details....

Stock Symbol: (AIM: HCM)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital